hims hers glp 1 & stock drops 30% after Novo Nordisk terminates deal Hims & Hers weight loss

Niazi explains that tirzepatide is a newer dual-agonist that targets both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which he says offers superior metabolic regulation and appetite suppression. Mounjaro is currently FDA-approved for type 2 diabetes, and Zepbound is also FDA-approved for weight loss

[DOI] [PubMed] [Google Scholar] 31.Kopp K.O., Glotfelty E.J., Li Y., Greig N.H

M., Van Raalte, D

Not suitable for patients with medullary thyroid carcinoma, MEN2, or pregnancy

S3D, GLP-1RA intervention was associated with a reduction in insulin levels at 2 h after OGTT when compared to metformin (MD = 22.18